Oct 27, 2022
Industry Veteran Joins Health Technology Pioneer to Bring Prescription Digital Therapeutics for Type 2 Diabetes and other Cardiometabolic Conditions to Market SAN FRANCISCO --(BUSINESS WIRE)--Oct. 27, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company
Sep 07, 2022
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 7, 2022-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe , Chief
Jul 11, 2022
SAN FRANCISCO --(BUSINESS WIRE)--Jul. 11, 2022-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced the publication of a manuscript
Displaying 11 - 20 of 65